Who are Teneli / Teneli + pio's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Januvia (sitagliptin), sitagliptin and acarbose, Teneli (Teneligliptin), alogliptin + pioglitazone, Linagliptin / Metformin Oral Tablet, SGLT2i+Metformin+Cofrogliptin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teneli-teneli-pio.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Teneli / Teneli + pio — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teneli / Teneli + pio (Teneli / Teneli + pio) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor; combination: DPP-4 inhibitor + thiazolidinedione. Area: Diabetes.

phase 3 DPP-4 inhibitor; combination: DPP-4 inhibitor + thiazolidinedione DPP-4 (dipeptidyl peptidase-4); pioglitazone targets PPAR-γ Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Teneli / Teneli + pio (Teneli / Teneli + pio) — Tanabe Pharma Corporation. Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals, improving glycemic control in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Teneli / Teneli + pio TARGET	Teneli / Teneli + pio	Tanabe Pharma Corporation	phase 3	DPP-4 inhibitor; combination: DPP-4 inhibitor + thiazolidinedione	DPP-4 (dipeptidyl peptidase-4); pioglitazone targets PPAR-γ
Januvia (sitagliptin)	Januvia (sitagliptin)	Zealand University Hospital	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes
Teneli (Teneligliptin)	Teneli (Teneligliptin)	Tanabe Pharma Corporation	marketed	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)
alogliptin + pioglitazone	alogliptin + pioglitazone	Kun-Ho Yoon	marketed	DPP-4 inhibitor + thiazolidinedione	DPP-4 and PPAR-γ
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
SGLT2i+Metformin+Cofrogliptin	SGLT2i+Metformin+Cofrogliptin	Huazhong University of Science and Technology	marketed	SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination)	SGLT2, mitochondrial complex I, DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor; combination: DPP-4 inhibitor + thiazolidinedione class)

Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teneli / Teneli + pio — Competitive Intelligence Brief. https://druglandscape.com/ci/teneli-teneli-pio. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing